RARE DISEASE
Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency
Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency
Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency
Synonyms: Classic 21-OHD CAH
Synonyms: Classic 21-OHD CAH
Synonyms: Classic 21-OHD CAH
Drug discovery
3
drugs
With orphan designations
Overview
Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency is an autosomal recessive disorder causing impaired cortisol/aldosterone synthesis, leading to adrenal insufficiency and androgen excess. Symptoms include ambiguous genitalia in 46,XX newborns, salt-wasting crises, accelerated growth with premature epiphyseal closure, and metabolic complications. Diagnosis involves elevated 17-OH-progesterone levels and CYP21A2 gene mutations [1][4][8]. Treatment focuses on glucocorticoid/mineralocorticoid replacement and androgen suppression [1][2][12].
Burden
Mortality: 20% lifetime risk of adrenal crisis-related death, with average 7-year life expectancy reduction [3][7]
Comorbidities: 2.8× increased diabetes risk, 2.4× dyslipidemia, 1.6× cardiovascular events [7][15]
Healthcare utilization: 171 lifetime sick-day rule implementations and 11 adrenal crisis hospitalizations per patient [3][19]
Therapies
Lifelong replacement: Hydrocortisone (10-20 mg/m²/day) + fludrocortisone (0.05-0.2 mg/day) [1][2][6]
Emergency protocols: Stress-dose glucocorticoids during illness/surgery to prevent adrenal crises [3][16]
Emerging approaches: Modified-release hydrocortisone (Chronocort®), CRH antagonists, and AAV-based gene therapy trials [14][18]
Categories: rare developmental anomalies during embryogenesis, rare endocrine diseases, rare genetic diseases, rare gynecological and obstetric diseases, rare infertility disorders, rare urogenital diseases
Research Papers
191 drug discovery papers about Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, with 2 first-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
191 drug discovery papers about Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, with 2 first-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
2026-08-06 | Congenital adrenal hyperplasia in children: a comprehensive review of clinical spectrum, diagnostic strategies, and management approaches
INTRODUCTION: Congenital adrenal hyperplasia (CAH) comprises a group of rare autosomal recessive disorders and is a leading cause of primary adrenal insufficiency in children. Most cases are due to classic 21-hydroxylase deficiency. Earlier diagnosis has been made possible with newborn screening, which has also reduced the risk of adrenal crises. This review is based on a search of PubMed, Embase, Scopus, and Medline for articles published from 2000 to 2025, using the terms "congenital adrenal hyperplasia", "21-hydroxylase deficiency", "primary adrenal insufficiency", and "steroidogenesis" with a focus on paediatric studies, clinical trials, systematic reviews, and consensus guidelines. CONTENT: The aims of clinical management are appropriate glucocorticoid and mineralocorticoid replacement, prevention of adrenal crises, monitoring of growth, puberty, and metabolic health. The main challenges include balancing androgen suppression with minimising glucocorticoid overexposure and monitoring for long-term complications such as early bone maturation and testicular adrenal rest tumours. Diagnostic accuracy and genotype-phenotype correlations have improved through advances in biochemical testing and molecular genetics. Newer and adjunctive therapies, including modified-release hydrocortisone, CRF1 receptor antagonists, adrenal-targeted drugs, and experimental gene therapies, may further improve disease management and simplify treatment. SUMMARY AND OUTLOOK: Effective management of CAH in children requires balancing optimal hormonal control with minimising treatment-related adverse effects. Newer and future therapies are expected to improve physiological management and long-term outcomes. Further research is needed to enhance individualised care and support transition to adult services.
2026-08-06 | Genetic characteristics and clinical features of pediatric congenital adrenal hyperplasia in Korea.
Despite the clinical importance of congenital adrenal hyperplasia (CAH), comprehensive data on subtype distribution, genetic characteristics, and the impact of newborn screening in Korea are limited. We analyzed the genetic profiles and clinical characteristics at diagnosis in 368 patients with CAH diagnosed before 19 years of age from the Multicenter Networks for Ideal Outcomes of Pediatric Rare Endocrine and Metabolic Diseases in Korea (OUTSPREAD) cohort. 21-hydroxylase deficiency (21-OHD) was the most prevalent CAH subtype (299 cases, 85.7%; 208 genetically confirmed and 91 clinically diagnosed), followed by lipoid congenital adrenal hyperplasia (LCAH; 9.5%) and 17α-hydroxylase deficiency (17α-OHD; 3.7%), accounting for 98.8% of cases. Frequent variants included c.293-13 C > G and p.Ile173Asn in 21-OHD, whereas p.Gln258Ter and p.His373Leu predominated in LCAH and 17α-OHD, consistent with East Asian population databases. Genotype-phenotype correlation analysis in 21-OHD demonstrated high positive predictive value, with genotypes characterized by minimal or absent residual enzyme activity associated with classic CAH in over 95% of cases. Among patients with salt-wasting 21-OHD, diagnosis occurred significantly earlier after newborn screening introduction, regardless of karyotype (46,XX: median 18.3 vs. 9.1 days, P = 0.031; 46,XY: 29.1 vs. 18.3 days, P = 0.019), along with a significant reduction in salt-wasting-related symptoms at diagnosis (46,XX: 33.3% vs. 10.5%, P = 0.031; 46,XY: 87.5% vs. 21.6%, P < 0.001). This national multicenter cohort study provides comprehensive genetic and clinical characterization of pediatric CAH in Korea, particularly in delineating CAH subtype distribution and the impact of newborn screening.
2026-07-14 | Reproduction and fertility issues in women with congenital adrenal hyperplasia: pathophysiology, management, and recent clinical advances.
Congenital adrenal hyperplasia (CAH), commonly caused by 21-hydroxylase deficiency (21-OHD), is an autosomal recessive disorder of adrenal steroidogenesis with significant implications for reproductive health. This review examines the pathophysiological mechanisms, fertility outcomes, and management strategies pertaining to reproductive function in women with classical and non-classical (NC) CAH. Fertility is generally reduced in women with classical CAH compared to the general population, owing to a combination of anatomical alterations from prenatal androgen exposure and reconstructive surgery, hypothalamic-pituitary-ovarian (HPO) axis dysregulation driven by excess adrenal androgens and progesterone, anovulation, and psychosexual factors, including altered gender-related behaviour and reduced reproductive intent. In NC CAH, fertility is only mildly impaired and most women can conceive; however, miscarriage rates are substantially higher in the absence of treatment. Optimised glucocorticoid replacement therapy is the cornerstone of management, restoring ovulatory cycles and improving conception rates in both phenotypes by suppressing adrenal androgen and progesterone excess. When ovulation fails to occur, induction with clomiphene citrate or gonadotropins may be employed; in vitro fertilisation with preimplantation genetic testing represents an option for refractory cases at high genetic risk. Pregnancy in CAH requires careful obstetric monitoring, glucocorticoid dose adjustment, and stress-dose coverage during labour. Prenatal treatment with dexamethasone to prevent virilisation of possibly affected female foetuses remains a subject of ongoing ethical and clinical debate. A multidisciplinary approach-encompassing endocrinology, reproductive medicine, surgery, and psychological support-is essential for optimising reproductive outcomes and quality of life in women with CAH.
2026-06-27 | Pharmacotherapeutic strategies for the management of congenital adrenal hyperplasia.
Classical congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21OHD) is characterized by impaired cortisol synthesis and excess adrenal androgen production. Current management relies on adrenal hormone replacement, however, achieving adequate androgen suppression often requires supraphysiologic glucocorticoid dosing with a risk of long-term morbidity. This review discusses current evidence on pharmacotherapeutic strategies for 21OHD, including evolving glucocorticoid formulations and delivery methods, as well as both established and emerging non-glucocorticoid therapies. The articles included in this review were identified through a PubMed search conducted up to April 2026. Glucocorticoids remain the cornerstone of therapy but are inherently limited by dose-dependent adverse effects. Emerging non-glucocorticoid agents such as the corticotropin-releasing factor type 1 (CRF1) receptor and melanocortin type 2 receptor (MC2R) antagonists represent the most clinically advanced strategy to reduce androgen excess, while enabling glucocorticoid dose reduction, and are likely to redefine standard care. Upstream targeting of the hypothalamic-pituitary-adrenal axis is expected to supersede downstream anti-androgen approaches. Future management will likely involve combination pharmacotherapies directed at the hypothalamic axis. Eventual use of CYP21A2 gene therapies may offer disease modification.
2026-05-27 | Characteristics of androgen metabolic pathways in patients with 21-hydroxylase deficiency and their association with disease control status.
To investigate the activity characteristics of distinct androgen metabolic pathways in patients with 21-hydroxylase deficiency (21OHD) and their correlation with disease control status, and to elucidate the metabolic pathway features and underlying mechanisms in poorly controlled patients. A total of 111 patients with confirmed 21OHD were enrolled in this study. Clinical data and steroid hormone profiles were collected, and robust standardized Z-scores were calculated for each steroid hormone. K-means clustering analysis was performed using the robust standardized Z-scores of 7 signature steroid hormones to stratify patients into a well-controlled group and a poorly controlled group. Differences in clinical characteristics, pathway activities and key enzyme conversion efficiencies were compared between and within the two groups. K-means clustering analysis classified 102 patients into the well-controlled group and 9 into the poorly controlled group. Multivariate analysis identified puberty as an independent risk factor for poor disease control (OR = 11.90, 95%CI:1.43-98.79, P = 0.02). Among pubertal patients, the poorly controlled group had a significantly higher relative weight of classical pathway androgen load than the well-controlled group (63.92% vs. 46.19%, P = 0.02), and the proportion of the classical pathway in the poorly controlled group was markedly higher than that of the 11-oxygenated and backdoor pathways (both P<0.05). Additionally, the conversion efficiency of the 21-deoxycortisol (21DOF) pathway was significantly decreased in the poorly controlled group (P = 0.004), suggesting relatively restricted CYP11B1 activity which drives the shift of androgen metabolism toward the classical pathway. In poorly controlled pubertal patients with 21OHD, the relative insufficiency of CYP11B1 activity and the dysregulation of the metabolic network jointly lead to the shift of androgen synthesis to the classical pathway, forming a "classical pathway dominance". This finding deepens the understanding of the pathological mechanism of 21OHD from the perspective of pathway dynamics and provides a novel theoretical basis for individualized clinical treatment of the disease.
2026-08-06 | Congenital adrenal hyperplasia in children: a comprehensive review of clinical spectrum, diagnostic strategies, and management approaches
INTRODUCTION: Congenital adrenal hyperplasia (CAH) comprises a group of rare autosomal recessive disorders and is a leading cause of primary adrenal insufficiency in children. Most cases are due to classic 21-hydroxylase deficiency. Earlier diagnosis has been made possible with newborn screening, which has also reduced the risk of adrenal crises. This review is based on a search of PubMed, Embase, Scopus, and Medline for articles published from 2000 to 2025, using the terms "congenital adrenal hyperplasia", "21-hydroxylase deficiency", "primary adrenal insufficiency", and "steroidogenesis" with a focus on paediatric studies, clinical trials, systematic reviews, and consensus guidelines. CONTENT: The aims of clinical management are appropriate glucocorticoid and mineralocorticoid replacement, prevention of adrenal crises, monitoring of growth, puberty, and metabolic health. The main challenges include balancing androgen suppression with minimising glucocorticoid overexposure and monitoring for long-term complications such as early bone maturation and testicular adrenal rest tumours. Diagnostic accuracy and genotype-phenotype correlations have improved through advances in biochemical testing and molecular genetics. Newer and adjunctive therapies, including modified-release hydrocortisone, CRF1 receptor antagonists, adrenal-targeted drugs, and experimental gene therapies, may further improve disease management and simplify treatment. SUMMARY AND OUTLOOK: Effective management of CAH in children requires balancing optimal hormonal control with minimising treatment-related adverse effects. Newer and future therapies are expected to improve physiological management and long-term outcomes. Further research is needed to enhance individualised care and support transition to adult services.
2026-08-06 | Genetic characteristics and clinical features of pediatric congenital adrenal hyperplasia in Korea.
Despite the clinical importance of congenital adrenal hyperplasia (CAH), comprehensive data on subtype distribution, genetic characteristics, and the impact of newborn screening in Korea are limited. We analyzed the genetic profiles and clinical characteristics at diagnosis in 368 patients with CAH diagnosed before 19 years of age from the Multicenter Networks for Ideal Outcomes of Pediatric Rare Endocrine and Metabolic Diseases in Korea (OUTSPREAD) cohort. 21-hydroxylase deficiency (21-OHD) was the most prevalent CAH subtype (299 cases, 85.7%; 208 genetically confirmed and 91 clinically diagnosed), followed by lipoid congenital adrenal hyperplasia (LCAH; 9.5%) and 17α-hydroxylase deficiency (17α-OHD; 3.7%), accounting for 98.8% of cases. Frequent variants included c.293-13 C > G and p.Ile173Asn in 21-OHD, whereas p.Gln258Ter and p.His373Leu predominated in LCAH and 17α-OHD, consistent with East Asian population databases. Genotype-phenotype correlation analysis in 21-OHD demonstrated high positive predictive value, with genotypes characterized by minimal or absent residual enzyme activity associated with classic CAH in over 95% of cases. Among patients with salt-wasting 21-OHD, diagnosis occurred significantly earlier after newborn screening introduction, regardless of karyotype (46,XX: median 18.3 vs. 9.1 days, P = 0.031; 46,XY: 29.1 vs. 18.3 days, P = 0.019), along with a significant reduction in salt-wasting-related symptoms at diagnosis (46,XX: 33.3% vs. 10.5%, P = 0.031; 46,XY: 87.5% vs. 21.6%, P < 0.001). This national multicenter cohort study provides comprehensive genetic and clinical characterization of pediatric CAH in Korea, particularly in delineating CAH subtype distribution and the impact of newborn screening.
2026-07-14 | Reproduction and fertility issues in women with congenital adrenal hyperplasia: pathophysiology, management, and recent clinical advances.
Congenital adrenal hyperplasia (CAH), commonly caused by 21-hydroxylase deficiency (21-OHD), is an autosomal recessive disorder of adrenal steroidogenesis with significant implications for reproductive health. This review examines the pathophysiological mechanisms, fertility outcomes, and management strategies pertaining to reproductive function in women with classical and non-classical (NC) CAH. Fertility is generally reduced in women with classical CAH compared to the general population, owing to a combination of anatomical alterations from prenatal androgen exposure and reconstructive surgery, hypothalamic-pituitary-ovarian (HPO) axis dysregulation driven by excess adrenal androgens and progesterone, anovulation, and psychosexual factors, including altered gender-related behaviour and reduced reproductive intent. In NC CAH, fertility is only mildly impaired and most women can conceive; however, miscarriage rates are substantially higher in the absence of treatment. Optimised glucocorticoid replacement therapy is the cornerstone of management, restoring ovulatory cycles and improving conception rates in both phenotypes by suppressing adrenal androgen and progesterone excess. When ovulation fails to occur, induction with clomiphene citrate or gonadotropins may be employed; in vitro fertilisation with preimplantation genetic testing represents an option for refractory cases at high genetic risk. Pregnancy in CAH requires careful obstetric monitoring, glucocorticoid dose adjustment, and stress-dose coverage during labour. Prenatal treatment with dexamethasone to prevent virilisation of possibly affected female foetuses remains a subject of ongoing ethical and clinical debate. A multidisciplinary approach-encompassing endocrinology, reproductive medicine, surgery, and psychological support-is essential for optimising reproductive outcomes and quality of life in women with CAH.
2026-06-27 | Pharmacotherapeutic strategies for the management of congenital adrenal hyperplasia.
Classical congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21OHD) is characterized by impaired cortisol synthesis and excess adrenal androgen production. Current management relies on adrenal hormone replacement, however, achieving adequate androgen suppression often requires supraphysiologic glucocorticoid dosing with a risk of long-term morbidity. This review discusses current evidence on pharmacotherapeutic strategies for 21OHD, including evolving glucocorticoid formulations and delivery methods, as well as both established and emerging non-glucocorticoid therapies. The articles included in this review were identified through a PubMed search conducted up to April 2026. Glucocorticoids remain the cornerstone of therapy but are inherently limited by dose-dependent adverse effects. Emerging non-glucocorticoid agents such as the corticotropin-releasing factor type 1 (CRF1) receptor and melanocortin type 2 receptor (MC2R) antagonists represent the most clinically advanced strategy to reduce androgen excess, while enabling glucocorticoid dose reduction, and are likely to redefine standard care. Upstream targeting of the hypothalamic-pituitary-adrenal axis is expected to supersede downstream anti-androgen approaches. Future management will likely involve combination pharmacotherapies directed at the hypothalamic axis. Eventual use of CYP21A2 gene therapies may offer disease modification.
2026-05-27 | Characteristics of androgen metabolic pathways in patients with 21-hydroxylase deficiency and their association with disease control status.
To investigate the activity characteristics of distinct androgen metabolic pathways in patients with 21-hydroxylase deficiency (21OHD) and their correlation with disease control status, and to elucidate the metabolic pathway features and underlying mechanisms in poorly controlled patients. A total of 111 patients with confirmed 21OHD were enrolled in this study. Clinical data and steroid hormone profiles were collected, and robust standardized Z-scores were calculated for each steroid hormone. K-means clustering analysis was performed using the robust standardized Z-scores of 7 signature steroid hormones to stratify patients into a well-controlled group and a poorly controlled group. Differences in clinical characteristics, pathway activities and key enzyme conversion efficiencies were compared between and within the two groups. K-means clustering analysis classified 102 patients into the well-controlled group and 9 into the poorly controlled group. Multivariate analysis identified puberty as an independent risk factor for poor disease control (OR = 11.90, 95%CI:1.43-98.79, P = 0.02). Among pubertal patients, the poorly controlled group had a significantly higher relative weight of classical pathway androgen load than the well-controlled group (63.92% vs. 46.19%, P = 0.02), and the proportion of the classical pathway in the poorly controlled group was markedly higher than that of the 11-oxygenated and backdoor pathways (both P<0.05). Additionally, the conversion efficiency of the 21-deoxycortisol (21DOF) pathway was significantly decreased in the poorly controlled group (P = 0.004), suggesting relatively restricted CYP11B1 activity which drives the shift of androgen metabolism toward the classical pathway. In poorly controlled pubertal patients with 21OHD, the relative insufficiency of CYP11B1 activity and the dysregulation of the metabolic network jointly lead to the shift of androgen synthesis to the classical pathway, forming a "classical pathway dominance". This finding deepens the understanding of the pathological mechanism of 21OHD from the perspective of pathway dynamics and provides a novel theoretical basis for individualized clinical treatment of the disease.
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
3 orphan drug designations for Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
3 orphan drug designations for Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
Drug | Therapy type | Regulator | Orphan designation | Approval | Sponsor |
|---|---|---|---|---|---|
adeno-associated virus vector expressing human 21-hydroxylase | gene therapies | FDA | 2018-08-30 | — | Adrenas Therapeutics Inc |
chromium picolinate and chromium histidinate | — | FDA | 2014-12-22 | — | JDS Therapeutics, LLC |
metformin | — | FDA | 2014-05-29 | — | EffRx Pharmaceuticals SA |
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI's forecasts to outperform average preclinical success rates. Whether you're expanding your R&D pipeline, evaluating a partnership, or simply have a question — we'd love to hear from you.